Overview

NCI Definition [1]:
An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.

Ec1456 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ec1456, 1 is phase 1 (0 open).

ER Negative, ER No Expression, and FOLR1 Expression are the most frequent biomarker inclusion criteria for ec1456 clinical trials.

Breast carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in ec1456 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ec1456
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ec1456 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
folate receptor-targeting folate-tubulysin conjugate ec1456, folate receptor-targeted tubulysin conjugate ec1456, folate receptor-targeting folate-tubulysin conjugate ec1456
NCIT ID [1]:
C113176

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.